• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal & Metabolism
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality
      • Environment, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Smartphone displaying cell structure
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/From Our Labs

mHealth: A revolution in healthcare

Novartis innovation and events such as mHealth Challenge enable patients to access data and personal information about their health via mobile devices.

Jun 24, 2014

Imagine having a mobile device that monitors your health so thoroughly that your personal health information will be sent to your physician or care team, enabling them to call you to discuss your symptoms and treatment options in real-time.

mHealth
Mobile phones provide healthcare practitioners and patients alike with the means to exchange information, data and imagery.

This scenario is no longer science fiction. Healthcare and technology companies are developing increasingly sophisticated mobile health applications, services and a range of products such as monitoring devices and wearable sensors. These will join growing numbers of products currently available, including some 97,000 healthcare apps which were downloaded by more than 250 million internet users last year, according to one recent market study.

“I have seen the impact of new devices during my own quest for a healthier life,” said Lita Sands, Head of Global Digital Transformation at Novartis. “The data they provide us, for instance knowing how many steps we’ve taken or how much effort our run took, gives us tremendous insight into our behavior. This knowledge provides the ability for us to change our ways.”

There’s an app for that

Mobile healthcare technology, sometimes called mHealth, is already changing the way doctors and patients interact. Medical education apps mean patients have access to information that helps them diagnose their problem even before they consult a doctor.

One example of mHealth services are tracking and monitoring apps that gather data of increasing detail and quality about a patient’s symptoms and general health while new communication platforms let doctors use these to interact with patients remotely. Data would only be shared with patient consent and in a way that is consistent with patient privacy. Sharing information can make healthcare more cost-effective as well as improving the quality of relationships between doctors and patients.

Novartis, like other healthcare companies, is increasing investment in this rapidly evolving area of technology. In the earliest days of app development, for instance, the company produced solutions for patients with chronic obstructive pulmonary disease (COPD), VaxTrak, an app aimed at helping families manage their children’s vaccination schedule, and Podhaler Pro for patients with Cystic Fibrosis.

Now, as technology evolves further, the company is exploring new ways to develop increasingly sophisticated digital resources. 

In 2013 Novartis organized an ‘mHealth Challenge’ – a 48-hour development marathon in the heart of Silicon Valley in the United States, aimed at identifying a novel way to use mobile technology to address a major health challenge. More than 160 developers and companies competed for cash prizes, designing a mobile solution that would help provide caregivers with novel tools to navigate the daily challenges of caring for a loved one with heart failure

The winning solution, created by Sense.ly, features an avatar medical assistant that allows health care professionals to remotely monitor the health of someone living with the disease.

Work is continuing to build on the ideas that came out of the challenge based on patient research, and it is set to become available later this year.

New services on the way

Growing collaboration with the technology sector could result in many new mHealth services in the coming years, says Michele Angelaccio, Associate Director US Mobile Health Strategy at Novartis Pharmaceuticals.

“For example, the start-up community has the expertise to create the innovative solution, but it’s up to us to determine how it’s relevant to our customer base and if it can ultimately drive improved health outcomes,” says Angelaccio. “We have a unique understanding of the challenges doctors and patients are facing, and can help guide start-ups in building and testing proposed solutions. Partnering with these health technologists is the cornerstone of our mobile health strategy. It will continue to propel us forward as an innovator and it is the means by which mHealth will help us to meet our customers’ needs and solve some of the business challenges we’re facing.

Novartis is already working on several mobile health solutions that could reach the market in the near future, including some that enable patients to undergo testing, diagnosis and treatment remotely.

“Through solutions like these, we intend to make a major change in the way care is delivered, and increase access to health services,” said Angelaccio.

Tags: 
Access to Healthcare, Digital, Emerging Technology, Mobile Devices
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Coronavirus
From Our Labs

A visual tour of scientific strategies for combating coronavirus

Wendi Yajnik, Global Head of Academic Partnerships and External Innovation for research
From Our Labs

Advancing medicine through collaboration

Special instrument controlled by a production associate
From Our Labs

Turning the power of nuclear technology into a medical force

You are here

  1. Home ›
  2. Stories ›
  3. From Our Labs

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.